Skip to main
  1. Stocks
  2. TuHURA Biosciences Inc
  3. Forecast
HURA

HURA Stock Forecast & Price Target

HURA Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TuHURA Biosciences is attractive because its lead IFx-2.0 program has already produced encouraging Phase 1b/2a data, with all three evaluable deep-seated MCC patients achieving durable partial responses and keytruda-based activity potentially de-risking the ongoing Phase 3 trial. The company also offers multiple near-term catalysts across MSDC inhibitors, TBS-2025, and anti-VISTA development, while FDA written responses and orphan-drug recognition support a credible regulatory path and broaden the long-term opportunity in MCC and AML. Financially, 3Q26 net loss was $0.10 per share versus expectations for $0.14, R&D and SG&A were only $3.7M and $2.0M, and ~$1.9M cash plus a $50M credit facility may fund operations into 2028.

Bears say

TuHURA Biosciences is a high-risk clinical-stage immuno-oncology company whose lead assets face substantial probability of failure because drug development often fails to show sufficient efficacy or safety in trials. Its ability to create value depends on FDA and other regulatory approvals, yet any delay or denial could materially impair commercialization and weigh on the share price. The outlook is further pressured by intense competition from better-capitalized biotech and pharmaceutical rivals, while anticipated additional equity financing to fund development raises dilution risk for existing shareholders.

HURA has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

HURA Analyst Forecast & Price Prediction

Get the latest HURA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HURA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TuHURA Biosciences Inc (HURA) Forecast

Analysts have given HURA a Buy based on their latest research and market trends.

According to 2 analysts, HURA has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TuHURA Biosciences Inc (HURA)


HURA Analyst Forecast & Price Prediction

Get the latest HURA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HURA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HURA stock data and trends